Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Nov 20;39(33):3651-3655.
doi: 10.1200/JCO.21.01886. Epub 2021 Sep 16.

Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer

Rebecca L Porter  1 , Ursula A Matulonis  1
Affiliations
Editorial

Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer

Rebecca L Porter et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ursula A. MatulonisHonoraria: AdvaxisConsulting or Advisory Role: Merck, Novartis, NextCureResearch Funding: Merck, Novartis, Tesaro, Syndax, Immunogen, Mersana, Leap Therapeutics, Fujifilm, SQZ BiotechTravel, Accommodations, Expenses: AstraZenecaNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
Summary of potential biomarkers under investigation for predicting response to therapy with immune checkpoint inhibitors. Representative candidates for biomarkers in tumor cells, the tumor microenvironment, and the circulation are depicted. In addition, clinical and host factors under investigation are included. B2M, beta-2 microglobulin; CTC, circulating tumor cell; ctDNA, circulating tumor DNA; GEP, gene expression profile; IFN, interferon; JAK1/2, Janus kinase 1/2; MMR, mismatch repair; ncRNA, noncoding RNA; NK, natural killer; PD-L1, programmed cell death ligand; TAM, tumor-associated macrophage; TCR, T-cell receptor; TMB, tumor mutational burden; TIL, tumor-infiltrating lymphocyte; Treg, regulatory T cell. Created with BioRender.
See this image and copyright information in PMC

Comment on

References

    1. Matulonis UA, Sood AK, Fallowfield L, et al. : Ovarian cancer. Nat Rev Dis Primers 2:16061, 2016 - PMC - PubMed
    1. Cancer Genome Atlas Research Network : Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011 - PMC - PubMed
    1. Yang SYC, Lheureux S, Karakasis K, et al. : Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Med 10:81, 2018 - PMC - PubMed
    1. Pujade-Lauraine E, Hilpert F, Weber B, et al. : Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302-1308, 2014 - PubMed
    1. Matulonis UA, Shapira-Frommer R, Santin AD, et al. : Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study. Ann Oncol 30:1080-1087, 2019 - PubMed

MeSH terms